Vivus Inc.

According to MLV, Vivus (NASDAQ: VVUS) Buy rating is reiterated. MLV said that it reiterates its BUY rating and $16 price target. “As a reminder, VVUS plans to conduct a retrospective fetal outcomes study using existing US electronic healthcare databases. The FORTRESS study will analyze the...

According to Jefferies, VIVUS (NASDAQ: VVUS) has determined that it is feasible to conduct a retrospective safety analysis (FORTRESS) of commercial topiramate use to rule out risk of birth defects with Qnexa. Jefferies said that VVUS reiterated its refiling guidance of 4Q11. “Although VVUS...

Investors in biotech company Vivus Inc. (Nasdaq: VVUS) are hoping that the company's new anti-obesity drug Qnexa will be a hit in the weight loss market. Vivus President Peter Tam said that Qnexa, which is awaiting U.S. approval, could potentially generate over $1 billion in sales per year in the...